evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

64 questions · 71 findings · 6 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 14 · 19.7%GRADE not reported 4 · 5.6%Very low 24 · 33.8%Low 11 · 15.5%Moderate 18 · 25.4%High 0 · 0%

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Change in body weight (kg) at 3 to < 12 months ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase followed by weight maintenance phase)

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Change in weight (kg) · overweight and obese participants without T2DM (weight‐reducing phase only)
2 findings from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Change in weight (kg) · overweight and obese participants with T2DM (weight‐reducing phase only)
2 findings from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Weight loss of at least 5% at ≥ 12 months ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase only)

It is very uncertain whether summary of findings table ‐ Low‐carbohydrate weight‐reducing diets changes weight loss of at least 5% at ≥ 12 months compared with balanced‐carbohydrate weight‐reducing diets (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Cardiovascular mortality ‐ not measured · overweight and obese participants with T2DM (weight‐reducing phase only)

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Constipation · overweight and obese participants with T2DM (weight‐reducing phase only)

It is very uncertain whether summary of findings table ‐ Low‐carbohydrate weight‐reducing diets changes constipation at 3 to < 12 months compared with balanced‐carbohydrate weight‐reducing diets (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Number of participants per group with weight loss of at least 5% at ≥ 12 months · overweight and obese participants without T2DM (weight‐reducing phase only)

It is very uncertain whether summary of findings table ‐ Low‐carbohydrate weight‐reducing diets changes number of participants per group with weight loss of at least 5% at… compared with balanced‐carbohydrate weight‐reducing diets (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Cardiovascular mortality ‐ not measured · overweight and obese participants without T2DM (weight‐reducing phase only)

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Low‐carbohydrate weight‐reducing diets vs balanced‐carbohydrate weight‐reducing diets

Constipation · overweight and obese participants without T2DM (weight‐reducing phase only)

It is very uncertain whether summary of findings table ‐ Low‐carbohydrate weight‐reducing diets changes constipation at 3 to < 12 months compared with balanced‐carbohydrate weight‐reducing diets (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Hypersensitivity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher hypersensitivity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Pancreatitis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher pancreatitis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Thromboembolism · children and adolescents (< 18 years of age) with first‐line ALL

The review found no eligible studies for this question.

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Osteonecrosis · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… showed no clear difference in osteonecrosis compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (low certainty).

1 finding from 1 review

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6 doses, 2500 IU/m2, IV) vs low‐risk standard (2 doses, 2500 IU/m2, IV)

Asparaginase‐associated toxicity · children and adolescents (< 18 years of age) with first‐line ALL

Summary of findings table ‐ Low‐risk with additional PEG‐asp (6… probably leads to higher asparaginase‐associated toxicity compared with low‐risk standard (2 doses, 2500 IU/m2, IV) (moderate certainty).

1 finding from 1 review